Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 2/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13905953 | 0.86 | ACHE (0.38) | HTR2AHTR2CHTR2BTNFRIPK1 | |
| SCHEMBL7550352 | 0.83 | ALDH1A1 (0.36) | HTR2AHTR2CHTR2BTNFRIPK1 | |
| SCHEMBL8249627 | 0.83 | ACHE (0.36) | HTR2AHTR2CHTR2BTNFRIPK1 | |
| SCHEMBL29620412 | 0.83 | ALDH1A1 (0.36) | HTR2AHTR2CHTR2BTNFRIPK1 | |
| SCHEMBL180373 | 0.83 | HTR2A (0.36) | HTR2AHTR2CHTR2BTNFRIPK1 | |
| SCHEMBL31567045 | 0.79 | TNF (0.33) | HTR2AHTR2CHTR2BTNFRIPK1 | |
| SCHEMBL9293416 | 0.79 | CYP3A4 (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL21996002 | 0.79 | TNF (0.33) | HTR2AHTR2CHTR2BTNFRIPK1 | |
| SCHEMBL31697168 | 0.79 | TRPA1 (0.41) | TNFRIPK1LMNADAO | |
| SCHEMBL15611127 | 0.79 | TRPA1 (0.41) | TNFRIPK1LMNADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | claimed |
| EP-1654238-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005009978-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | claimed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | claimed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3889156-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| US-11066402-B2 | 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-07-20 | — | — | US | disclosed |
| EP-2831073-B1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B]PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | RHIZEN PHARMACEUTICALS S A (CH) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020108659-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2020-06-04 | — | — | WO | disclosed |
| WO-2020023792-A1 | COMBINATION THERAPY FOR NICOTINE ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2019079209-A1 | COMBINATION THERAPY FOR PREVENTING ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| US-10207985-B2 | Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| US-20080274304-A1 | Functionalized Photoreactive Compounds | ROLIC AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
| EP-1654238-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005009978-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
| US-4879423-A | 2-CHLORO-3,6-DIFLUOROBENZYL 3-(2-CHLORO-3,3,3-TRIFLUOROPROP-1-EN-1-YL) -2,2-DIMETHYLCYCLOPROPANECARBOXYLATE, INSECTICIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-11-07 | — | — | US | disclosed |
| US-4778822-A | SOIL ROOT WORM CONTROL WITH 2-CHLORO-3,6-DIFLUOROBENZYL 3-(2-CHLORO-3,3,3-TRIFLUOROPROP-1-EN-1-YL) -2,2-DIMETHYLCYCLOPROPANE CARBOXYLATE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | HTR2A 3274/4885HTR2C 2616/4885HTR2B 1931/4885 |
| US-20080274304-A1 | Functionalized Photoreactive Compounds | PCNA, PIN1, MAP1LC3C | HTR2A 2854/4885HTR2C 1349/4885HTR2B 1139/4885 |
| US-11066402-B2 | 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases | MET, PRKCH, HGFAC | HTR2A 1434/4885HTR2C 981/4885HTR2B 1693/4885 |
| US-10207985-B2 | Compounds | CYP1B1, DDT, CYP1A1 | HTR2A 3550/4885HTR2C 1645/4885HTR2B 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.